70 related articles for article (PubMed ID: 20304710)
21. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
[TBL] [Abstract][Full Text] [Related]
22. [Lithium as an adjuvant in the radioiodine therapy of thyroid cancer].
Schraube P; Kimmig B; zum Winkel K
Nuklearmedizin; 1984 Jun; 23(3):151-4. PubMed ID: 6435095
[TBL] [Abstract][Full Text] [Related]
23. [Effect of the plan of therapy on prognosis in thyroid cancer].
Schümichen C; Schmitt E; Scheuffele C; Blattmann H; Pauli-Harnasch C
Nuklearmedizin; 1983 Apr; 22(2):97-105. PubMed ID: 6866782
[TBL] [Abstract][Full Text] [Related]
24. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
25. Role of 131I in the treatment of well differentiated thyroid cancer.
Woodrum DT; Gauger PG
J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
[TBL] [Abstract][Full Text] [Related]
26. Redifferentiating agents in non-radioiodine avid cancer.
Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904
[TBL] [Abstract][Full Text] [Related]
27. Thyroxine dosing after I131Radioiodine ablation for differentiated thyroid cancer.
Clarke K; Gill V; Gerrard G
Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):559-60. PubMed ID: 21530195
[No Abstract] [Full Text] [Related]
28. Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management.
Newbold KL; Flux G; Wadsley J
Clin Oncol (R Coll Radiol); 2017 May; 29(5):307-309. PubMed ID: 28139379
[TBL] [Abstract][Full Text] [Related]
29. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
Bulotta S; Celano M; Costante G; Russo D
Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
[TBL] [Abstract][Full Text] [Related]
30. Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response.
Campopiano MC; Ghirri A; Prete A; Lorusso L; Puleo L; Cappagli V; Agate L; Bottici V; Brogioni S; Gambale C; Minaldi E; Matrone A; Elisei R; Molinaro E
Front Endocrinol (Lausanne); 2023; 14():1133958. PubMed ID: 37152950
[TBL] [Abstract][Full Text] [Related]
31. Preparation for radioiodine therapy: how to increase therapeutic efficacy and accelerate unbound radioiodine excretion.
Matović M
Vojnosanit Pregl; 2013 May; 70(5):504-10. PubMed ID: 23789291
[No Abstract] [Full Text] [Related]
32. Outcome of pregnancy following treatment of well-differentiated thyroid cancer with 131iodine.
Balan KK; Critchley M
Br J Obstet Gynaecol; 1992 Dec; 99(12):1021-2. PubMed ID: 1477008
[No Abstract] [Full Text] [Related]
33. Phytochemicals in thyroid cancer: analysis of the preclinical studies.
Bulotta S; Capriglione F; Celano M; Pecce V; Russo D; Maggisano V
Endocrine; 2021 Jul; 73(1):8-15. PubMed ID: 33587255
[TBL] [Abstract][Full Text] [Related]
34. Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: A novel agent.
Vatsa R; Sood A
Indian J Med Res; 2020 Nov; 152(Suppl 1):S258-S259. PubMed ID: 35345242
[No Abstract] [Full Text] [Related]
35. To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment.
Tuncel M; Vrachimis A; Campenni A; de Keizer B; Verburg FA; Kreissl MC; Ovcaricek PP; Geliashvili T; Giovanella L
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3316-3319. PubMed ID: 35581502
[No Abstract] [Full Text] [Related]
36. Ethanol injection into autonomous thyroid adenomas.
Hegedüs L; Karstrup S; Hansen JM
Clin Endocrinol (Oxf); 1993 Apr; 38(4):439-40. PubMed ID: 8319377
[No Abstract] [Full Text] [Related]
37. Radioiodine treatment: an historical and future perspective.
Borges de Souza P; McCabe CJ
Endocr Relat Cancer; 2021 Sep; 28(10):T121-T124. PubMed ID: 33690155
[No Abstract] [Full Text] [Related]
38. Radioiodine for thyroid cancer: sometimes, less is best.
Padovani Rdo P
Arch Endocrinol Metab; 2016 Feb; 60(1):2-4. PubMed ID: 26909476
[No Abstract] [Full Text] [Related]
39. Radioiodine and flame sensors.
Tajiri J; Goshi K; Fukata S
Lancet; 2007 Sep; 370(9591):934. PubMed ID: 17869630
[No Abstract] [Full Text] [Related]
40. Polymorphisms in adiposity-related genes are associated with age at menarche and menopause in breast cancer patients and healthy women.
Kim KZ; Shin A; Lee YS; Kim SY; Kim Y; Lee ES
Hum Reprod; 2012 Jul; 27(7):2193-200. PubMed ID: 22537818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
